16 Epilogue
What it would mean to take reversible ageing seriously — as a science, a medicine and a fact about the kind of creatures we are becoming.
A study of an unfinished science earns the right to a conclusion only by resisting the temptation to write one. The work surveyed in these pages is not finished, and a tidy verdict would falsify it. What can be done at the close is something more modest and, perhaps, more useful: to take the long view of the argument as it accumulated, to name the few interpretive habits that decide whether a reader meets the next decade’s claims as a citizen or as a mark, and to say plainly where the disciplines of evidence and of judgement leave the matter. The thread that ran through every part — that ageing has the form of a reversible loss of biological information, and that the distance between that form and a clinic is the whole of the unfinished work — is the thread to follow one last time.
A reader who began with the science and arrived here has watched a single idea harden under repeated pressure. It is worth restating how unusual that trajectory is. Most accounts of a fast-moving field accumulate excitement; the chapters examined here accumulated discrimination, each part narrowing the conditions under which the central claim could be believed rather than widening the scope of what was promised. The pattern is the opposite of hype, and recognising it is the first of the interpretive habits this closing means to leave with the reader.
16.1 What the argument actually established
The molecular parts did not argue that ageing is curable. They argued something at once more precise and more strange: that the decline of an old organism has, in significant part, the character of corrupted information rather than worn-out hardware. The case was built tier by tier and never by assertion. A word that dissolves under questioning was converted into a researchable object with a regular mathematical shape; that object was decomposed into a structured and openly contested catalogue of processes; and one entry in the catalogue — the drift of the epigenetic marks that hold a cell’s identity in place — was shown to behave less like a peer of the others than like the ground on which several of them stand (López-Otín et al., 2023; Yang et al., 2023). The therapeutic chapters then walked through that map one door at a time: slowing the accumulation of damage through the nutrient sensors, subtracting the senescent cells that inflame ageing tissue, and finally the boldest move of all, the attempt to rewrite a drifted cell’s age by the brief, pulsed application of the factors that returned a specialised cell to its embryonic state in the first place (Browder et al., 2022; Ocampo et al., 2016; Takahashi & Yamanaka, 2006). Regenerative medicine, asked from a different angle, converged on the same problem from outside: every route to a repaired tissue turned out to be, at bottom, a way of restoring or protecting cellular identity against the drift of age.
The convergence is the point, and it is what raises the loss-of-identity reading above the status of a slogan. An organising idea earns confidence not when one experiment supports it but when independent lines of work, designed for other purposes, keep arriving at it unbidden — the information theory built on an engineered mouse, the organ-crossing mesenchymal drift found in a meta-analysis of human tissues, the senescent cell read as a locked loss of identity, the regenerative graft understood as identity preserved (Lu et al., 2025; Yücel & Gladyshev, 2026). That several roads lead to one clearing does not prove the clearing is the centre of the forest. It does mean the map is not arbitrary, and that the field has acquired, for the first time, a candidate for the single upstream failure beneath the twelve downstream faults.
And yet the discipline that made the science credible is exactly the discipline that forbids the leap the marketplace most wants to make. The standing rule of these pages — that a result demonstrated in a mouse or a dish is a hypothesis about a human being, not a fact about one — is not a rhetorical hedge bolted on for caution’s sake. It is the load-bearing wall of the entire structure, and the history reviewed here is, read honestly, a catalogue of what happens when it is removed. The strong free-radical theory was beautiful, mechanistically clean and, in its clinical form, refuted by trials enrolling hundreds of thousands of people, some of whom it harmed (Bjelakovic et al., 2007). A raised concentration of a youth-associated metabolite turned out to be a property of the bottle rather than of the person who swallowed it. A cross-sectional correlate, real in animals, evaporated when matched human cohorts were examined longitudinally (Marcangeli et al., 2025). A drug with the strongest preclinical evidence in the entire field engaged its target, proved safe, and moved its clinical endpoint not one step beyond placebo in a thousand-patient trial (Mannick et al., 2021). Each of these was a failure of the same inference, and the inference is the one a press release is built to perform.
16.2 The interpretive habits that decide everything
If there is a single transferable skill these chapters exist to install, it is the capacity to hold two facts in mind without letting either cancel the other: that the biology of reversible ageing is real, and that essentially none of it has yet been shown to lengthen a healthy human life. A reader who drops the first fact becomes the cynic, who dismisses a genuine scientific revolution because its marketing is tawdry. A reader who drops the second becomes the credulous consumer, for whom every moved biomarker is a postponed funeral. The critical reader holds both, and the holding is uncomfortable by design.
The discomfort matters because the noise around this field is not noise of the ordinary kind, and the reasons were diagnosed at the close of the scientific section rather than left to indignation. A sector with concentrated incentives to overstate clinical readiness, a cohort of public scientists whose visibility increasingly selects for findings whose narrative travels, and a media ecosystem that treats the gap between a press release and a peer-reviewed result as a matter of style — these converge, none of them necessarily dishonest, on a single posture of optimism that shifts the public’s sense of how close are we far ahead of the evidence. The protection against that drift is not specialist expertise, which most readers cannot acquire, but a short set of questions any reader can carry: what species and what age; what endpoint; what effect size and confidence interval; pre-registered or found after the fact; replicated where; and who benefits if the claim is believed. The last question is not a presumption of bad faith. It is an adjustment of the prior, and the reader who makes it is the reader least likely to be moved by the incentive structures that shape what gets published, how, and with what emphasis.
There is a subtler interpretive trap that the marketplace works hardest to set, and it deserves isolating because the science reviewed in the preceding parts has made it newly seductive. The genuine, named, sometimes astonishing successes of the converging technologies — the speech interface returning communication to a person locked in by paralysis, the base edit confined to the cells of a single infant with a fatal metabolic disease (Musunuru et al., 2025) — are, every one of them, restorative: attempts to return a damaged human towards the species-typical norm. The enhancement claims that borrow their glamour — the consumer brain-stimulation headset, the regimen that promises a postponed senescence to the already healthy — are precisely the ones the evidence does not support (Gems & Magalhães, 2024; Kang et al., 2024). To treat the demonstrated success of restoration as a down payment on the promise of enhancement is to repeat, in the showroom, the category error the discarded paradigms committed in the laboratory. The line between healing and upgrading is the line the science honours and the sales pitch blurs, and a reader who keeps it sharp has acquired most of what a critical reading of longevity claims requires.
16.3 How a clean science is dressed for sale
The most disquieting feature of this field is the ease with which a difficult, heavily qualified, mouse-bound body of work can be repackaged as an available human service. The repackaging follows a recognisable grammar. It begins with a real result — a genuine rejuvenation of a tissue in an animal, a methylation clock that does read something about biological age — and then performs a series of small, individually plausible substitutions: the animal becomes the human, the biomarker becomes the benefit, the laboratory becomes the clinic, the cyclic protocol carefully titrated in a mouse becomes an infusion sold by the course. No single step is an outright lie. The compression of the whole sequence is the lie, and by the time it reaches a glossy waiting room in a low-regulation jurisdiction, the qualifications that made the original science honest have been quietly discarded along the way (Demaria, 2025; Hamzelou, 2025).
The setting in which this grammar pays best is instructive, because it reveals what the longevity market is often really selling. The premium longevity clinic does not, for the most part, address the disease burden of ageing in the populations that carry most of it. It offers, to a clientele defined by exceptional purchasing power, a suite of procedures whose register slides without friction between the medical, the cosmetic and the frankly positional — the panel of biomarkers as a status object, the bespoke supplement stack as a marker of access, the rejuvenation regimen as a way of signalling membership of a group that need not age on the ordinary schedule. The boundary between a reparative therapy, an aesthetic intervention and a sociocultural emblem of standing dissolves precisely where it is most profitable to dissolve it, and the dissolving is not incidental to the business model but central to it. What is sold is rarely a validated extension of healthy life. It is the appearance of privileged access to one, which is a different and far more durable commodity, because it cannot be refuted by a failed endpoint.
The same logic governs the diagnostic theatre that increasingly anchors these clinics. The whole-body scan and the hundred-marker blood panel are sold as preventive vigilance, a way of catching decline before it announces itself; what they reliably produce, in a population selected for being well, is a high yield of findings of no clinical consequence — the incidental shadow, the marginal value, the cyst that was never going to matter — each of which sets off its own cascade of follow-up imaging, biopsy, specialist referral and quiet dread (Demaria, 2025; Hamzelou, 2025). The net effect is not measurably longer or healthier life but the conversion of healthy people into perpetual patients, and the medicalisation of ordinary ageing into a condition to be monitored, optimised and billed. That a difficult science should end, at the point of sale, in so much testing of the well and so little benefit to the sick is the clearest possible sign that the thing being marketed is not the thing the laboratory produced. The pattern is amplified, finally, by a media ecology in which a charismatic endorsement — a celebrity, a primetime segment, an influencer with an undisclosed commercial stake — can carry a “cellular regeneration” device or a rejuvenation regimen to a mass audience faster than any correction can follow, and in a vocabulary engineered to sound like the science it is not.
The following are recurring categories of “anti-ageing” offering for which the human evidence is, as of this writing, absent, weak or contradicted — assembled not to single out particular vendors but to illustrate the kinds of claim a critical reader should meet with the six questions of Chapter 11. None is presented here as fraudulent in every instance; several rest on real biology whose translation to a marketed human benefit has simply not been shown.
- Antioxidant supplement regimens sold to slow ageing: the strong free-radical paradigm they invoke was refuted in large randomised trials, some showing increased mortality (Bjelakovic et al., 2007).
- NAD+-precursor courses (NMN, NR) marketed as rejuvenation: blood NAD+ rises reliably; the downstream clinical outcomes that would matter to a person are mostly null or small (Migaud et al., 2024; Vinten et al., 2025).
- Taurine and similar “deficiency-reversal” supplements: the human cross-sectional correlation did not survive a matched longitudinal test (Marcangeli et al., 2025).
- Human growth hormone and “secretagogue” protocols sold as rejuvenation therapy: distributing growth hormone for anti-ageing purposes is unlawful in the United States, and the practice has been a marker of the field’s quackery for two decades (Perls, 2004).
- mTOR-inhibitor and “rapalogue” protocols sold ahead of evidence: the cleanest confirmatory trial matched placebo on its clinical endpoint despite engaging its target (Mannick et al., 2021).
- Young-plasma transfusion and “parabiosis-inspired” infusions: marketed on animal-model imagery without replicated human benefit, and the object of regulatory warning (Hamzelou, 2025).
- Unregulated stem-cell and “exosome” rejuvenation offered through clinic tourism: deployed far outside the conditions of the international guidelines that govern legitimate translation (Lovell-Badge et al., 2021).
- Consumer neuro-enhancement devices (transcranial-stimulation headsets, “brain-training” subscriptions) sold for cognitive ageing: an umbrella review of randomised trials finds the effects weak, inconsistent and unestablished in healthy users (Kang et al., 2024).
- Topical over-the-counter “anti-ageing” cosmeceuticals promising to reverse the appearance of age: a billion-dollar category in which, for most marketed compounds, controlled evidence of efficacy is thin or absent (Huang & Miller, 2007).
- Bespoke peptide, hormone and “longevity panel” packages at premium clinics: the broad category of unproven, commercially driven offerings whose register slides between medicine, cosmetics and status (Demaria, 2025; Gems & Magalhães, 2024).
The unifying diagnosis is not that the underlying biology is fake — much of it is excellent — but that a result in a model organism, or a movement in an upstream marker, has been sold as a benefit to a human life that has not been demonstrated to receive one.
16.4 When big science is rented
The clinics are the retail end of a distortion that begins much further upstream, in the relationship between concentrated private capital and the researchers whose names lend it credibility. The migration of ageing science out of academic laboratories and into heavily capitalised ventures was, in itself, neither sinister nor surprising; translation needs money on a scale that grant councils do not supply, and several of the field’s most serious investigators now sit, reasonably enough, inside well-funded firms. The danger is more specific and more structural than any individual’s integrity. It is what happens to the public understanding of a science when the incentives of capital reach back into the laboratory and begin, gently, to select for the findings whose story sells.
The mechanism is a kind of borrowed credibility. A leading researcher’s reputation — earned over decades, by exactly the disciplined, mouse-bound, heavily qualified work honoured throughout these pages — becomes an asset that can be deployed in registers far removed from the bench: the keynote, the podcast, the prediction of a rejuvenation pill within the decade, the assurance to a lay audience that the body can be reset towards youth not slightly but by most of its accumulated age (Sinclair, 2026). The claims are not, in their laboratory form, fabrications; they are extrapolations, and the gap between the careful conditional of a paper’s discussion section and the confident futurology of a stage is where the credibility is spent. When figures from outside biology — technologists and investors whose authority derives from unrelated triumphs — adopt the same vocabulary, pronouncing ageing a “very solvable problem” whose cause will prove “incredibly obvious”, or a matter of reprogramming a body that is merely “pre-programmed to die”, the distance from the underlying evidence has widened to the point where the rhetoric is doing work the science cannot yet support (Musk, 2026). The bodily synchronisation that such voices invoke as proof that the problem is tractable — the observation that no one has an old left arm and a young right one — is real, and is, on the loss-of-identity reading, a genuine clue; but the inference from “there is a clock” to “the clock is nearly ours to set” is precisely the inference the field’s own failures should have retired.
The deeper hazard is epistemic, and it is worth stating without euphemism. A research programme financed to deliver a marketable human intervention is under a quiet, persistent pressure to narrate its animal results as though the species barrier were a formality rather than the central unsolved problem. The pressure does not require anyone to lie. It requires only that the conditional be dropped a little earlier in each retelling, that the caveat migrate a little further down the page, that the mouse be allowed to stand in for the human a little more readily in the keynote than it would in the manuscript. The accumulation of these small, individually defensible compressions, distributed across a whole sector and amplified by a media ecosystem that rewards confidence over hedging, produces a public picture of imminence that the technical literature does not contain. The corrective is not cynicism about the scientists, most of whom are doing careful work under real constraints. It is the structural literacy to see that the same name can be both a rigorous investigator and a marketing instrument, and that the reader’s task is to know which register is being used (Gems & Magalhães, 2024; Lyu et al., 2024).
16.5 Living, and governing, as though it were true
Suppose the science delivers — not immortality, which the responsible part of the field has never promised, but the real and more modest thing it works towards: a genuine compression of late-life illness, the long dusk replaced by a day that stays bright closer to its end. What would it mean to take that prospect seriously before it arrives, while it is still uncertain enough to be shaped?
It would mean, first, refusing the substitution that the whole apparatus of hype is built to perform: the substitution of lifespan for healthspan, of duration for the quality of the years, of the future one wants for the future one has. The economic case for intervening in ageing is enormous if the biology cooperates, and the size of that prize is itself a reason to invest in the science honestly; but the dividend remains a counterfactual whose magnitude is well characterised and whose realisation is not, and a society that mistook the model for the outcome would be building policy on a number that values a slowdown which has not occurred (Olshansky et al., 2024; Scott et al., 2021). It would mean, second, attending now to a gradient that no technology yet proposed can close on its own: a geroprotective therapy introduced into a world of vast and patterned inequality in healthy life expectancy will, by default, reach those who already have the diagnostic and clinical infrastructure to use it, and may widen the gap it is sold as narrowing. The institutions that will decide who receives a postponed decline are deciding it for a queue of future older selves who do not yet have a vote, and the discipline of reasoning as if from the queue rather than the front of it is the nearest thing political philosophy offers to a guide (Daniels, 2008).
And it would mean, finally, keeping distinct the two things the marketplace most profits from confusing: the restoration of an individual life and the redesign of the human kind. The science surveyed here is overwhelmingly the former — it returns an ageing organism towards a function it once had, and on every framework examined in the closing chapters that is therapy, not transgression. The posture the argument finally recommends is not a prohibition but a stance: prefer the reversible to the irreversible, the moderate to the radical, the validated to the promised; distrust the conflation of a medicine for the old with a programme to remake the species; and remember that biology, having handed the species a dial it did not previously possess, falls silent exactly where the question turns to what the dial is for (Agar, 2025; Williams, 1973). That question is not answered by any experiment surveyed here, and was never going to be. The work of these chapters was to establish that the dial is real, to measure how far it can and cannot yet be turned, and to arm the reader against those who would sell its motion before it has been shown. Where the setting should sit is a decision the species has only begun to face, and will have to make with the clearest possible view of how easily a genuine science can be dressed up as something it is not.
These pages opened on Augustine’s complaint that he knew what time was until he was asked to explain it. Ageing has worn the same false familiarity, and the achievement of the science examined here is to have made it strange enough to study and, in animals, to move. The corresponding achievement asked of the reader is to keep it strange — to refuse the easy certainties of both the salesman and the sceptic, and to meet what comes next with the one disposition the preceding chapters have tried throughout to model: a hope disciplined by evidence, and an evidence undimmed by hope.